MediBeacon® Transdermal GFR System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers began in January 2026 NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% ...

Core Viewpoint - MediBeacon Inc., in which INNOVATE Corp. holds a 44.7% equity interest, has received FDA approval for its next-generation TGFR System, which includes the TGFR Reusable Sensor, enhancing kidney function assessment technology [1][7]. Group 1: Product Details - The TGFR System allows for kidney function assessment at the point of care by measuring the clearance rate of Lumitrace (relmapirazin), a non-radioactive, non-iodinated fluorescent GFR agent [2]. - The TGFR Reusable Sensor is designed for patient comfort, ease of application, and reusability, reducing costs compared to the previously approved single-use TGFR Sensor [3]. - The TGFR System records Lumitrace fluorescence intensity transdermally at a rate of 2.5 readings per second, providing real-time data on kidney function [12]. Group 2: Clinical Validation and Research - The TGFR System was featured in a lead peer-reviewed article in the Journal of the American Society of Nephrology, highlighting its application across various levels of kidney function and skin colors [4]. - MediBeacon has a strong research background with over 700 peer-reviewed publications and conference abstracts utilizing the transdermal GFR methodology [5]. Group 3: Market Strategy and Future Plans - MediBeacon plans to offer early access to the TGFR System at leading academic medical centers in the U.S. and China, with initial sales expected to begin in the first quarter of 2026 [5][7]. - The company aims to integrate transdermal GFR technology into ongoing heart failure studies, emphasizing its potential to improve patient monitoring and accuracy in kidney function assessment [6]. Group 4: Company Overview - INNOVATE Corp. is focused on key areas of the new economy, including Infrastructure, Life Sciences, and Spectrum, employing approximately 3,100 people across its subsidiaries [8]. - MediBeacon specializes in fluorescent tracer agents and transdermal detection technology, holding over 60 granted U.S. patents and more than 245 patents worldwide [9].

Core Viewpoint - MediBeacon's Transdermal GFR System (TGFR) has received approval in China, marking a significant advancement in kidney function assessment technology, which is expected to improve patient management in chronic kidney disease (CKD) [1][4][5]. Company Overview - INNOVATE Corp. is the parent company of MediBeacon, focusing on medical technology and has a commitment to expanding access to innovative healthcare solutions globally [8]. - MediBeacon specializes in fluorescent tracer agents and their transdermal detection, holding over 60 U.S. patents and more than 245 patents worldwide [9][10]. Product Details - The TGFR system includes Lumitrace (relmapirazin) injection, MediBeacon TGFR Monitor, and MediBeacon TGFR Sensor, which together facilitate the assessment of kidney function by measuring the clearance rate of the fluorescent agent [2][12]. - Lumitrace is a non-radioactive, non-iodinated compound designed for effective kidney function measurement without interference from medications or demographic factors [11][7]. Market Opportunity - Chronic Kidney Disease (CKD) affects approximately 11% of the 1.4 billion population in China, presenting a substantial market opportunity for the TGFR system [3]. - The approval of the TGFR system in China is seen as a major step in enhancing access to kidney health management tools [5]. Clinical Implications - The TGFR system aims to provide a more accurate and immediate assessment of kidney function compared to traditional methods, which can be influenced by various non-renal factors [5][6]. - The technology is expected to transform kidney disease management by allowing real-time assessment at the point of care, potentially improving patient outcomes [7].